FolioLanternBeta
KYMRKymera Therapeutics, Inc.

Bruce Booth

Director at Kymera Therapeutics, Inc., as of Jul 2, 2026Sold $2.2M of stock in the past 12 months: 100% under a disclosed plan.

Updated Oct 15, 2026 from SEC filings · covers Oct 16, 2025 to Oct 15, 2026
0
shares held after the latest filing, Kymera Therapeutics, Inc.
Vested shares reported on Forms 3, 4 and 5 only. Not the insider's whole wealth.
24K
shares sold, past 12 months
4
days with sales
$1.1M
largest single day, Jun 17, 2026
4
companies filed for

Share of stake sold at Kymera Therapeutics, Inc. is not shown: the holdings do not reconcile with the filings. Why

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled
OctNovDecJanFebMarApr 2026: $1.1M under a disclosed plan$1.1MAprMayJun 2026: $1.1M under a disclosed planJunJulAugSepOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Kymera Therapeutics, Inc. (KYMR)DirectorAug 20, 2020Jul 2, 2026
Sionna Therapeutics, Inc. (SION)DirectorFeb 6, 2025Jun 18, 2026
Dianthus Therapeutics, Inc. (DNTH)Former DirectorJun 20, 2018Jun 30, 2022
Cogent Biosciences, Inc. (COGT)Former DirectorMar 28, 2018Jul 6, 2020

Also a director at

Sionna Therapeutics, Inc. (SION), Dianthus Therapeutics, Inc. (DNTH) (no filing in the last 18 months), Cogent Biosciences, Inc. (COGT) (no filing in the last 18 months)

Recent filings

The last 4 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.